Shanghai Bao Pharmaceuticals (HKG:2659) said Chinese regulators approved its KJ017 injection, according to a Hong Kong bourse filing Wednesday.
KJ017 is an injectable version of human hyaluronidase designed to administer fluids or drugs subcutaneously, or under the skin, that the firm said is better than animal-derived hyaluronidase products.